Carlos Alberto Bordini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carlos Alberto Bordini has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Davy Henrique Sousa Pelliciari
Municipal University Center of Franca, Franca, Sao Paulo, Brazil
4 shared publications - Hilton Mariano da Silva Junior
Hospital Municipal de Campinas Doutor Mário Gatti, Campinas São Paulo, Brasil
4 shared publications José G. Speciali
Department of Neurology, School of Medicine at Ribeirão Preto, São Paulo University, Brazil
2 shared publications- Juliana Baleki Borri
Pontifícia Universidade Católica de Campinas, Campinas, São Paulo, Brasil
2 shared publications - Marcelo Eduardo Bigal
Ventus Therapeutics, Waltham, MA, U.S.A.
2 shared publications - Ariana Pereira Germano
Municipal University Center of Franca
1 shared publication
Latest Publications
- 17 October 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (11) , 862
TAC-Tic syndromes: a case series on the complex overlap between trigeminal autonomic cephalalgias and trigeminal neuralgia
- 17 October 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (11) , 862
TAC-Tic syndromes: a case series on the complex overlap between trigeminal autonomic cephalalgias and trigeminal neuralgia
- Open Access
- 30 January 2026
- Published by Headache Medicine in Headache Medicine
- Vol. 17 (1) , 34-42
Primary stabbing headache – a narrative review
IntroductionPrimary stabbing headache (PSH), also known as “ice-pick headache”, is characterized by sudden, ultrashort stabs of head pain and may be under-recognized due to overlap with other headache disorders and mimics.ObjectiveTo provide a narrative overview of PSH, summarizing epidemiology, proposed mechanisms, clinical features, differential diagnosis, taxonomic evolution across ICHD editions, and reported treatments.MethodologyA targeted search in PubMed/MEDLINE, SciELO and LILACS was complemented by manual reference screening, including key references cited in ICHD-3 (section 4.7). Keywords related to PSH were combined with “clinical presentation”, “epidemiology”, “diagnostic criteria” and “treatment”. Articles in English, Portuguese or Spanish were considered.ResultsFrequency estimates vary by definition and setting. Pediatric sources generally describe PSH as an uncommon diagnosis among children with recurrent headaches, with onset often during school-age years. In adults, estimates range from low values in population studies using stricter definitions to higher rates in community surveys eliciting ultrashort stabbing “jabs”. Attacks last seconds and occur as single jabs or brief series, with variable topography and laterality. Associated symptoms may reflect comorbidity (especially migraine); prominent cranial autonomic features should prompt reassessment for trigeminal autonomic cephalalgias or secondary causes when red flags are present. Evidence for treatment is largely uncontrolled; indomethacin is most frequently reported, while other agents appear in small series.ConclusionPSH is generally benign, but its reported frequency and phenotype are heterogeneous across studies. ICHD-3 broadened diagnostic inclusion beyond V1 distribution, potentially improving clinical fit. Careful differential diagnosis remains essential in atypical presentations.
- 30 January 2026
- Published by Headache Medicine in Headache Medicine
- Vol. 17 (1) , 34-42
Open AccessPrimary stabbing headache – a narrative review
IntroductionPrimary stabbing headache (PSH), also known as “ice-pick headache”, is characterized by sudden, ultrashort stabs of head pain and may be under-recognized due to overlap with other headache disorders and mimics.ObjectiveTo provide a narrative overview of PSH, summarizing epidemiology, proposed mechanisms, clinical features, differential diagnosis, taxonomic evolution across ICHD editions, and reported treatments.MethodologyA targeted search in PubMed/MEDLINE, SciELO and LILACS was complemented by manual reference screening, including key references cited in ICHD-3 (section 4.7). Keywords related to PSH were combined with “clinical presentation”, “epidemiology”, “diagnostic criteria” and “treatment”. Articles in English, Portuguese or Spanish were considered.ResultsFrequency estimates vary by definition and setting. Pediatric sources generally describe PSH as an uncommon diagnosis among children with recurrent headaches, with onset often during school-age years. In adults, estimates range from low values in population studies using stricter definitions to higher rates in community surveys eliciting ultrashort stabbing “jabs”. Attacks last seconds and occur as single jabs or brief series, with variable topography and laterality. Associated symptoms may reflect comorbidity (especially migraine); prominent cranial autonomic features should prompt reassessment for trigeminal autonomic cephalalgias or secondary causes when red flags are present. Evidence for treatment is largely uncontrolled; indomethacin is most frequently reported, while other agents appear in small series.ConclusionPSH is generally benign, but its reported frequency and phenotype are heterogeneous across studies. ICHD-3 broadened diagnostic inclusion beyond V1 distribution, potentially improving clinical fit. Careful differential diagnosis remains essential in atypical presentations.
- Open Access
- 16 October 2025
- Published by Headache Medicine in Headache Medicine
- Vol. 16 (3) , 171-175
SUNCT syndrome associated with pituitary Rathke's cyst and responsive to indomethacin: a case report
Introduction Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA) is a rare group of headaches classified by the International Classification of Headache Disorders (ICHD-3) in its group 3, the trigeminal-autonomic headaches, and, therefore a primary headache. Rathke’s cleft cysts are sellar or suprasellar non-neoplastic cystic lesions arising from remnants of Rathke’s pouch. These cysts are asymptomatic, but when large, they compress adjacent structures and may present with headache, visual disturbance, and pituitary dysfunction. Cases of secondary SUNCT/SUNA have been reported; however, this is the first report of SUNCT/SUNA associated with a Rathke's cleft cyst. Case Report A 47-year-old, other while healthy male has been experiencing for the last five years a strictly right sided pain in the orbital and in the frontoparietal area. The pain was felt as if a nail was being driven into his cranium slowly for 5-15 seconds, with intense pain persisting in the area for a few more seconds. Pain intensity was described as excruciating (10/10), a frequency of 4-18 a day, duration of 4- 30 seconds, associated to 2-3 eardrops and moderate conjunctival hyperemia ipsilateral to the pain. Attacks never could be attacks triggered by cutaneous stimuli. Physical and neurological examinations were normal. MRI showed a cystic lesion in the anterior pituitary gland consistent with a Rathke's cleft cyst. The pain was refractory to carbamazepine, amitriptyline, topiramate, and methadone, but was responsive to indomethacin. Comment To the best of our knowledge, this case report appears to be the first on SUNCT: a) associated with Rathke's cleft cyst; and b) responsive to indomethacin.
- 16 October 2025
- Published by Headache Medicine in Headache Medicine
- Vol. 16 (3) , 171-175
Open AccessSUNCT syndrome associated with pituitary Rathke's cyst and responsive to indomethacin: a case report
Introduction Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA) is a rare group of headaches classified by the International Classification of Headache Disorders (ICHD-3) in its group 3, the trigeminal-autonomic headaches, and, therefore a primary headache. Rathke’s cleft cysts are sellar or suprasellar non-neoplastic cystic lesions arising from remnants of Rathke’s pouch. These cysts are asymptomatic, but when large, they compress adjacent structures and may present with headache, visual disturbance, and pituitary dysfunction. Cases of secondary SUNCT/SUNA have been reported; however, this is the first report of SUNCT/SUNA associated with a Rathke's cleft cyst. Case Report A 47-year-old, other while healthy male has been experiencing for the last five years a strictly right sided pain in the orbital and in the frontoparietal area. The pain was felt as if a nail was being driven into his cranium slowly for 5-15 seconds, with intense pain persisting in the area for a few more seconds. Pain intensity was described as excruciating (10/10), a frequency of 4-18 a day, duration of 4- 30 seconds, associated to 2-3 eardrops and moderate conjunctival hyperemia ipsilateral to the pain. Attacks never could be attacks triggered by cutaneous stimuli. Physical and neurological examinations were normal. MRI showed a cystic lesion in the anterior pituitary gland consistent with a Rathke's cleft cyst. The pain was refractory to carbamazepine, amitriptyline, topiramate, and methadone, but was responsive to indomethacin. Comment To the best of our knowledge, this case report appears to be the first on SUNCT: a) associated with Rathke's cleft cyst; and b) responsive to indomethacin.
- Open Access
- 31 March 2025
- Published by Headache Medicine in Headache Medicine
- Vol. 16 (1) , 71-74
Petasites hybridus: evidence 1A on migraine prophylaxis
Petasites hybridus extract is part of the therapeutic arsenal for migraine prophylaxis. In this commentary, we discuss the study by Lipton et al. (2004), published in Neurology, which presents a high-quality clinical trial demonstrating the efficacy of Petasites hybridus for migraine prevention. The study, conducted by renowned researchers, classifies Petasites hybridus as a Level A treatment (established efficacy based on >2 Class I trials). Despite this strong evidence, questions often arise regarding the appropriate clinical scenarios for prescribing this medication. In addition to analyzing the findings of this seminal study, this commentary explores potential indications for Petasites hybridus in clinical practice.
- 31 March 2025
- Published by Headache Medicine in Headache Medicine
- Vol. 16 (1) , 71-74
Open AccessPetasites hybridus: evidence 1A on migraine prophylaxis
Petasites hybridus extract is part of the therapeutic arsenal for migraine prophylaxis. In this commentary, we discuss the study by Lipton et al. (2004), published in Neurology, which presents a high-quality clinical trial demonstrating the efficacy of Petasites hybridus for migraine prevention. The study, conducted by renowned researchers, classifies Petasites hybridus as a Level A treatment (established efficacy based on >2 Class I trials). Despite this strong evidence, questions often arise regarding the appropriate clinical scenarios for prescribing this medication. In addition to analyzing the findings of this seminal study, this commentary explores potential indications for Petasites hybridus in clinical practice.
- Open Access
- 30 September 2024
- Published by Headache Medicine in Headache Medicine
- Vol. 15 (3) , 218-222
Boundaries of visual phenomena in migraine: the charles bonnet’s syndrome - report of two cases
IntroductionTwo patients were referred to a tertiary headache center due to complex visual phenomena that might be related to migraine aura. Eventually, it turned out that they were Charles Bonnet syndrome (CBS) patients. The syndrome is characterized by vivid visual hallucinations in the absence of other psychiatric symptoms, often in patients with optical morphophysiological disorders. The pathophysiology of CBS remains uncertain, and the syndrome lacks robust diagnostic criteria. So far, reports on CBS are scarce in Brazilian neurological literature, leading to challenges in identification and diagnosis. The condition is primarily recognized through anamnesis and clinical examination.ObjectiveTo report two cases of CBS to draw the attention of headache specialists about this syndrome.Case reportsThe first case involves a 93-year-old male patient, retired, who reported experiencing vivid hallucinations sometimes of an old white car and sometimes a group of children. Despite the clarity of these visions, the patient remained aware that they were not real. In the second case, a 70-year-old male farmer began experiencing hallucinations involving scratches, scribbles, letters, stones, and women in his visions. ConclusionHere two cases of CBS were reported concerning a not so rare condition, but for sure very uncommon to headache specialists.
- 30 September 2024
- Published by Headache Medicine in Headache Medicine
- Vol. 15 (3) , 218-222
Open AccessBoundaries of visual phenomena in migraine: the charles bonnet’s syndrome - report of two cases
IntroductionTwo patients were referred to a tertiary headache center due to complex visual phenomena that might be related to migraine aura. Eventually, it turned out that they were Charles Bonnet syndrome (CBS) patients. The syndrome is characterized by vivid visual hallucinations in the absence of other psychiatric symptoms, often in patients with optical morphophysiological disorders. The pathophysiology of CBS remains uncertain, and the syndrome lacks robust diagnostic criteria. So far, reports on CBS are scarce in Brazilian neurological literature, leading to challenges in identification and diagnosis. The condition is primarily recognized through anamnesis and clinical examination.ObjectiveTo report two cases of CBS to draw the attention of headache specialists about this syndrome.Case reportsThe first case involves a 93-year-old male patient, retired, who reported experiencing vivid hallucinations sometimes of an old white car and sometimes a group of children. Despite the clarity of these visions, the patient remained aware that they were not real. In the second case, a 70-year-old male farmer began experiencing hallucinations involving scratches, scribbles, letters, stones, and women in his visions. ConclusionHere two cases of CBS were reported concerning a not so rare condition, but for sure very uncommon to headache specialists.
- Open Access
- 30 September 2024
- Published by Headache Medicine in Headache Medicine
- Vol. 15 (3) , 170-174
SHOULD ANTI-CGRP MONOCLONAL ANTIBODIES ALWAYS BE THE DRUG OF FIRST CHOICE FOR MIGRAINE PROPHYLAXIS IN BRAZIL? - A PHARMACOECONOMIC STUDY
Efficacy (success of therapy under ideal conditions), efficiency (the relationship between the costs and outcomes of a specific intervention), and effectiveness (the balance between efficacy and efficiency in clinical practice) are measures used to evaluate health interventions. Thus, in private practice and the public health system, the knowledge of these pharmacoeconomic data should influence the appropriate treatment choice. Migraine prophylaxis falls within this context. Traditional medications are available in the public health system, while galcanezumab is not routinely available. The present study aims to analyze the efficacy and effectiveness of galcanezumab and traditional therapeutic alternatives (amitriptyline, divalproex sodium, and topiramate). Efficacy data were obtained from the relevant literature (PubMed) and cost values from the ABCFARMA magazine. The economic impact analysis considered the cost of living for an economically active adult in Brazil based on the Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatística, IBGE) and the Institute for Applied Economic Research (Instituto de Pesquisa Econômica Aplicada, IPEA). Efficacy: amitriptyline: 40%; divalproex sodium: 30%; topiramate: 31%; galcanezumab: 50%. Their annual costs were: amitriptyline R$ 240.00; sodium divalproate R$ 876.00; topiramate R$ 600.00; galcanezumab R$ 13,992.00. Efficiency: amitriptyline 200%; divalproex sodium 41.1%; topiramate 62%; galcanezumab 4%. Ultimately, effectiveness is amitriptyline 120%; divalproex sodium 35.7%; topiramate 46.5%; galcanezumab 27%. Galcanezumab is the most effective; however, in a broader analysis, where payers, availability, and patient conditions are considered, evaluating efficacy alone may not be feasible in practical contexts and, therefore, anti-CGRP antibodies will not always be the first-line medications in migraine prophylaxis.
- 30 September 2024
- Published by Headache Medicine in Headache Medicine
- Vol. 15 (3) , 170-174
Open AccessSHOULD ANTI-CGRP MONOCLONAL ANTIBODIES ALWAYS BE THE DRUG OF FIRST CHOICE FOR MIGRAINE PROPHYLAXIS IN BRAZIL? - A PHARMACOECONOMIC STUDY
Efficacy (success of therapy under ideal conditions), efficiency (the relationship between the costs and outcomes of a specific intervention), and effectiveness (the balance between efficacy and efficiency in clinical practice) are measures used to evaluate health interventions. Thus, in private practice and the public health system, the knowledge of these pharmacoeconomic data should influence the appropriate treatment choice. Migraine prophylaxis falls within this context. Traditional medications are available in the public health system, while galcanezumab is not routinely available. The present study aims to analyze the efficacy and effectiveness of galcanezumab and traditional therapeutic alternatives (amitriptyline, divalproex sodium, and topiramate). Efficacy data were obtained from the relevant literature (PubMed) and cost values from the ABCFARMA magazine. The economic impact analysis considered the cost of living for an economically active adult in Brazil based on the Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatística, IBGE) and the Institute for Applied Economic Research (Instituto de Pesquisa Econômica Aplicada, IPEA). Efficacy: amitriptyline: 40%; divalproex sodium: 30%; topiramate: 31%; galcanezumab: 50%. Their annual costs were: amitriptyline R$ 240.00; sodium divalproate R$ 876.00; topiramate R$ 600.00; galcanezumab R$ 13,992.00. Efficiency: amitriptyline 200%; divalproex sodium 41.1%; topiramate 62%; galcanezumab 4%. Ultimately, effectiveness is amitriptyline 120%; divalproex sodium 35.7%; topiramate 46.5%; galcanezumab 27%. Galcanezumab is the most effective; however, in a broader analysis, where payers, availability, and patient conditions are considered, evaluating efficacy alone may not be feasible in practical contexts and, therefore, anti-CGRP antibodies will not always be the first-line medications in migraine prophylaxis.
- Open Access
- 14 September 2023
- Published by Headache Medicine in Headache Medicine
- Vol. 14 (2) , 124-127
Insights on the terminology and on some pathophysiological aspects of cluster headache and related conditions
IntroductionCluster headache and the more recently reported “related conditions”, namelyChronic Paroxysmal Hemicrania, Short-lasting, unilateral, Neuralgiform Headachewith Conjunctival Injection and Tearing (SUNCT) Syndrome and (possibly also)Hemicrania Continua, are one of the fascinating groups of conditions in Neurologywhose cardinal features are the almost absolute unilaterality of pain, its excruciatingseverity, besides the prominent mainly facial autonomic disturbances and overall theintriguing biorhythmicity.Beyond any doubt, the progress of our knowledge about themechanisms of these conditions has been considerable, but there is always room forreflection on where we are and where we can go.ObjectiveThe objectives of the present study are to analyze the metrics of publications onthe pathophysiology of these conditions, to explore in detail how proper the term”Trigeminal Autonomic Cephalgia” is, and to comment on their numerous synonyms.CommentMuch is needed to know the exact structures and circuitry involved in the pathophysiology of these conditions; accordingly, a non-compromising and just descriptive termmight be useful. Along this line of reasoning and bearing in mind the cardinal pointsof such conditions, namely, pain in the trigeminal territory, prominent autonomicsymptoms, prominent chronobiological features, and the excruciating character ofthe pain, a terminological possibility would be: Unilateral with Prominent Rhythmicityand Autonomic Symptoms Excrutiating Cephalgia (UPRASEC).
- 14 September 2023
- Published by Headache Medicine in Headache Medicine
- Vol. 14 (2) , 124-127
Open AccessInsights on the terminology and on some pathophysiological aspects of cluster headache and related conditions
IntroductionCluster headache and the more recently reported “related conditions”, namelyChronic Paroxysmal Hemicrania, Short-lasting, unilateral, Neuralgiform Headachewith Conjunctival Injection and Tearing (SUNCT) Syndrome and (possibly also)Hemicrania Continua, are one of the fascinating groups of conditions in Neurologywhose cardinal features are the almost absolute unilaterality of pain, its excruciatingseverity, besides the prominent mainly facial autonomic disturbances and overall theintriguing biorhythmicity.Beyond any doubt, the progress of our knowledge about themechanisms of these conditions has been considerable, but there is always room forreflection on where we are and where we can go.ObjectiveThe objectives of the present study are to analyze the metrics of publications onthe pathophysiology of these conditions, to explore in detail how proper the term”Trigeminal Autonomic Cephalgia” is, and to comment on their numerous synonyms.CommentMuch is needed to know the exact structures and circuitry involved in the pathophysiology of these conditions; accordingly, a non-compromising and just descriptive termmight be useful. Along this line of reasoning and bearing in mind the cardinal pointsof such conditions, namely, pain in the trigeminal territory, prominent autonomicsymptoms, prominent chronobiological features, and the excruciating character ofthe pain, a terminological possibility would be: Unilateral with Prominent Rhythmicityand Autonomic Symptoms Excrutiating Cephalgia (UPRASEC).
- Open Access
- 27 October 2022
- Published by Headache Medicine in Headache Medicine
- p. 27
Trends in physiopathology research of primary headaches over the last 50 years
Introduction The headache field, mainly migraine, is passing through a transformative era of new treatments. These breakthroughs would not be possible without the evolving knowledge on mechanisms of headaches. However, there are still unmet needs for headaches' understanding and treatments. Objectives Assess whether there is a trend in the number of publications regarding physiopathology of each primary headache disorders (PHD) in the past 50 years. Secondarily, we aimed to evaluate how the SARS-CoV-2 pandemics impacted on physiopathology research of PHD. Methods PHD were divided hierarchically in first- and second-digit, according to ICHD-3 criteria. PubMed database was searched using both the name of the PHD and MeSH terms related to physiopathology. Each search yielded the number of publications for a determined PHD along the period selected (1971-2021). Data were retrieved and separated in two groups: a) per decades (1971-2020); and b) per year (2011-2021). Ratios between every two timepoints in each group were calculated, as well as a total ratio for the whole interval. Results Either divided per decades, or divided annually for the last 10 years, migraine had the highest absolute number of pathophysiology publications, significantly above the other PHD. Divided per decades, with exception of tension-type headache (TTH), all the other PHD groups have increased their number of publications over time. Meanwhile, TTH in the last decade decreased the total number of mechanisms research. The number of papers published in 2020 was lower than in 2019 for TTH, trigeminal autonomic cephalalgias (TACs) and group 4 "other PHD" (4.OPHD), migraine kept practically the same number. Conclusion There is a clear disparity in the number of publications on mechanisms of each PHD, being migraine well above TTH, TACs and 4.OPHD. As expected, the recent COVID pandemics has clearly impaired pathophysiologic research in the headache field. Keywords: Headache, Migraine, Mechanisms, Physiopathology, Research.
- 27 October 2022
- Published by Headache Medicine in Headache Medicine
- p. 27
Open AccessTrends in physiopathology research of primary headaches over the last 50 years
Introduction The headache field, mainly migraine, is passing through a transformative era of new treatments. These breakthroughs would not be possible without the evolving knowledge on mechanisms of headaches. However, there are still unmet needs for headaches' understanding and treatments. Objectives Assess whether there is a trend in the number of publications regarding physiopathology of each primary headache disorders (PHD) in the past 50 years. Secondarily, we aimed to evaluate how the SARS-CoV-2 pandemics impacted on physiopathology research of PHD. Methods PHD were divided hierarchically in first- and second-digit, according to ICHD-3 criteria. PubMed database was searched using both the name of the PHD and MeSH terms related to physiopathology. Each search yielded the number of publications for a determined PHD along the period selected (1971-2021). Data were retrieved and separated in two groups: a) per decades (1971-2020); and b) per year (2011-2021). Ratios between every two timepoints in each group were calculated, as well as a total ratio for the whole interval. Results Either divided per decades, or divided annually for the last 10 years, migraine had the highest absolute number of pathophysiology publications, significantly above the other PHD. Divided per decades, with exception of tension-type headache (TTH), all the other PHD groups have increased their number of publications over time. Meanwhile, TTH in the last decade decreased the total number of mechanisms research. The number of papers published in 2020 was lower than in 2019 for TTH, trigeminal autonomic cephalalgias (TACs) and group 4 "other PHD" (4.OPHD), migraine kept practically the same number. Conclusion There is a clear disparity in the number of publications on mechanisms of each PHD, being migraine well above TTH, TACs and 4.OPHD. As expected, the recent COVID pandemics has clearly impaired pathophysiologic research in the headache field. Keywords: Headache, Migraine, Mechanisms, Physiopathology, Research.
- Open Access
- 27 October 2022
- Published by Headache Medicine in Headache Medicine
- p. 33
Cephalalgia heterotopica: a case series of extratrigeminal cluster headache
Introduction Cluster headache is a very disabling neurological disorder that usually presents with unilateral severe headache associated with ipsilateral cranial autonomic symptoms. Even among the typical cases, there is a considerable diagnostic delay and most patients will have seen three general practitioners before being referred to neurology services, some having been to colleagues in dentistry or otorhinolaryngology. The extratrigeminal presentation of this condition poses a great obstacle to a proper diagnostic workup. Objective This consecutive case series study aimed to report clinical features, treatment, and outcome of 3 patients with extratrigeminal Cluster Headache. Materials and Methods Case series of our Headache Clinic. Data disclosure was authorized by the patients through an informed consent form. Results Two males and one female were evaluated. The ages were 53, 64, and 71 years. The mean age of symptoms onset was 50, 60, and 66 years, respectively. Two patients described excruciating shoulder pain and one presents severe pain in the malar area. All patients reported prominent autonomic ipsilateral symptoms such as lacrimation, conjunctival injection, nasal symptoms, and restlessness accompanying pain attacks. Preventive treatment with verapamil and occipital nerve block was useful. Conclusion Extratrigeminal cluster presentation is a diagnostic challenge. Proper recognition of these cases prevents unnecessary examination and treatment trials and directly benefits the patients since effective treatment is already available. A proper case definition of this rare clinical presentation may provide new insight into our understanding of the cluster headache mechanisms. Keywords: Cluster headache, Extratrigeminal headache, Shoulder pain.
- 27 October 2022
- Published by Headache Medicine in Headache Medicine
- p. 33
Open AccessCephalalgia heterotopica: a case series of extratrigeminal cluster headache
Introduction Cluster headache is a very disabling neurological disorder that usually presents with unilateral severe headache associated with ipsilateral cranial autonomic symptoms. Even among the typical cases, there is a considerable diagnostic delay and most patients will have seen three general practitioners before being referred to neurology services, some having been to colleagues in dentistry or otorhinolaryngology. The extratrigeminal presentation of this condition poses a great obstacle to a proper diagnostic workup. Objective This consecutive case series study aimed to report clinical features, treatment, and outcome of 3 patients with extratrigeminal Cluster Headache. Materials and Methods Case series of our Headache Clinic. Data disclosure was authorized by the patients through an informed consent form. Results Two males and one female were evaluated. The ages were 53, 64, and 71 years. The mean age of symptoms onset was 50, 60, and 66 years, respectively. Two patients described excruciating shoulder pain and one presents severe pain in the malar area. All patients reported prominent autonomic ipsilateral symptoms such as lacrimation, conjunctival injection, nasal symptoms, and restlessness accompanying pain attacks. Preventive treatment with verapamil and occipital nerve block was useful. Conclusion Extratrigeminal cluster presentation is a diagnostic challenge. Proper recognition of these cases prevents unnecessary examination and treatment trials and directly benefits the patients since effective treatment is already available. A proper case definition of this rare clinical presentation may provide new insight into our understanding of the cluster headache mechanisms. Keywords: Cluster headache, Extratrigeminal headache, Shoulder pain.
- Open Access
- 27 October 2022
- Published by Headache Medicine in Headache Medicine
- p. 31
Cephalalgia heterotopica: a case series of lower half face migraine
Introduction Migraine is a common and very disabling neurological disease. It typically causes severe throbbing pain or a pulsing sensation, usually on one side of the head. It's often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. According to the definition of headache, the pain should be located in the head or in the face above the orbitomeatal line. Beyond this classical view, recent evidence has shown that it could be an arbitrary boundary, and other clinical features can prevail during the diagnosis process. Objective This consecutive case series study aimed to report clinical features, treatment, and outcome of 5 patients with a lower-half facial presentation of migraine. Materials and Methods Case series of our Headache Clinic. Data disclosure was authorized by the patients through an informed consent form. Results Of the 5 patients, 3 were women and 2 were men. Mean age was 34, 6 (13-56 years). The mean age of symptoms onset was 15,2 (11-29 years). All patients described a throbbing, moderate to severe pain in the malar area. Four patients reported frequent phonophobia and photophobia accompanying pain attacks. One patient reported great relief of pain with rizatriptan and another with sumatriptan. Preventive treatment with pizotifen, propranolol, flunarizine, amitriptyline, divalproex sodium, and pregabalin was useful. All patients underwent extensive dental and otolaryngological evaluation and treatment, which were worthless. Conclusion Migraine orofacial presentation is a diagnostic challenge. Proper recognition of these cases not only prevents unnecessary examination and treatment trials but directly benefits the patients since effective treatment is already available. A proper case definition of this rare clinical presentation may provide new insight into our understanding of the migraine mechanisms. Keywords: Facial pain, Migraine, Lower half-face migraine.
- 27 October 2022
- Published by Headache Medicine in Headache Medicine
- p. 31
Open AccessCephalalgia heterotopica: a case series of lower half face migraine
Introduction Migraine is a common and very disabling neurological disease. It typically causes severe throbbing pain or a pulsing sensation, usually on one side of the head. It's often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. According to the definition of headache, the pain should be located in the head or in the face above the orbitomeatal line. Beyond this classical view, recent evidence has shown that it could be an arbitrary boundary, and other clinical features can prevail during the diagnosis process. Objective This consecutive case series study aimed to report clinical features, treatment, and outcome of 5 patients with a lower-half facial presentation of migraine. Materials and Methods Case series of our Headache Clinic. Data disclosure was authorized by the patients through an informed consent form. Results Of the 5 patients, 3 were women and 2 were men. Mean age was 34, 6 (13-56 years). The mean age of symptoms onset was 15,2 (11-29 years). All patients described a throbbing, moderate to severe pain in the malar area. Four patients reported frequent phonophobia and photophobia accompanying pain attacks. One patient reported great relief of pain with rizatriptan and another with sumatriptan. Preventive treatment with pizotifen, propranolol, flunarizine, amitriptyline, divalproex sodium, and pregabalin was useful. All patients underwent extensive dental and otolaryngological evaluation and treatment, which were worthless. Conclusion Migraine orofacial presentation is a diagnostic challenge. Proper recognition of these cases not only prevents unnecessary examination and treatment trials but directly benefits the patients since effective treatment is already available. A proper case definition of this rare clinical presentation may provide new insight into our understanding of the migraine mechanisms. Keywords: Facial pain, Migraine, Lower half-face migraine.